CS 003
Alternative Names: CS-003; R-113281Latest Information Update: 12 May 2008
At a glance
- Originator Daiichi Sankyo Inc
- Class Antiasthmatics
- Mechanism of Action Tachykinin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 22 Jan 2004 Phase-II clinical trials in Asthma in USA (Inhalation)
- 22 Jan 2004 Phase-II clinical trials in Asthma in USA (PO)